The short answer
NAD+ carries two negatively charged phosphates and does not cross plasma membranes. Extracellular NAD+ is also degraded by ectoenzymes including CD38. This is why the research field administers smaller precursors, and why effects following NAD+ administration most plausibly run through its breakdown products.
Key facts
- Barrier
- Two negative phosphate charges
- Membrane crossing
- Does not occur passively
- Extracellular degradation
- CD38 and other ectoenzymes
- Likely fate
- Cleaved to smaller precursors
- Field's approach
- Administer NR or NMN instead
- NR size
- 255.25 Da, far smaller
The physical problem
A lipid bilayer is a hydrophobic barrier, and charged molecules do not cross it without a transporter. NAD+ carries two negative charges on its pyrophosphate bridge at physiological pH and is 663 Da besides. Both properties point the same way: it stays outside unless something actively carries it in.
What happens to it outside
CD38 is an ectoenzyme (an enzyme with its active site facing the outside of the cell) and it cleaves NAD+ as a substrate. So extracellular NAD+ is not simply sitting inert waiting to be taken up; it is being consumed. Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by increasing CD38 activity, which places this enzyme at the centre of the ageing story.
Research material referenced
NAD+ 500mg, third-party HPLC tested
Where the breakdown products go
Cleaving NAD+ yields smaller fragments including nicotinamide-containing species, and those are the molecules cells can take up and rebuild NAD+ from. This is the important inference: whatever effect follows administering NAD+ most plausibly proceeds through degradation to precursors, then uptake, then internal resynthesis, not through NAD+ arriving intact.
Which is why the trials use precursors
Nicotinamide riboside at 255.25 Da and nicotinamide mononucleotide at 334.22 Da are both far smaller and both have cellular uptake routes. Every substantial randomised human trial in this field, NADPARK, Orr's 2024 study, Yoshino's 2021 Science paper,used a precursor. That is not because NAD+ was unavailable to those researchers.
What follows practically
Administering NAD+ directly is a less direct route to raising cellular NAD+ than administering a precursor, not a more direct one, because the intact molecule cannot make the final step. It is a real pharmacological point and it is almost never made in commercial material about this compound.
Frequently asked questions
Can NAD+ enter cells?
Not passively. Two negative phosphate charges and 663 Da prevent it crossing a lipid bilayer.
What is CD38?
An ectoenzyme that cleaves NAD+ outside the cell. Covarrubias 2020 reported senescent cells drive tissue NAD+ decline by increasing its activity.
So how could administered NAD+ have any effect?
Most plausibly by being degraded to smaller precursors that cells can take up and rebuild NAD+ from internally.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedCovarrubias AJ et al., Senescent cells promote tissue NAD+ decline during ageing via CD38. Nat Metab 2020 (PMID 33199924)pubmed.ncbi.nlm.nih.gov
- PubMedCovarrubias AJ et al. Nat Rev Mol Cell Biol 2021 (PMID 33353981)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Nicotinamide riboside (CID 439924)pubchem.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More NAD+ articles
- NAD+ Precursors: Nicotinamide Riboside and NMNNR at 255.25 Da and NMN at 334.22 Da. What each is, how they enter the salvage pathway, and why almost all trial data uses them.
- NAD+ and Ageing: What Is Actually EstablishedTissue NAD+ falls with age, and Covarrubias 2020 identified a mechanism - senescent cells raising CD38. Whether restoring it helps is a separate question.
- What the Human Trials Actually FoundNADPARK, Orr 2024, Yoshino's Science paper and Yi 2023. Real randomised data - and uniformly on precursors rather than NAD+ itself.
- NAD+, NMN and NR: Three Points on One PathwayNot three competing compounds but three positions in a single conversion sequence. Which has the trial data, and which is hardest to deliver.
- NAD+ Storage: Different Chemistry, Different RisksNot a peptide, so peptide degradation logic does not apply. The bonds at risk are glycosidic and pyrophosphate, and both hydrolyse readily.